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Indicators 
   2018  2019  2020  
Indicator Definition Population Value 
(95%CI) 
N Value  
(95%CI) 
N Value  
(95%CI) 
N 
Average coverage per cycle Mean of coverage in 
cycles 1,2,3 and 4 
Children aged 3-59 








Mean number of 
treatments per child 
Mean number of SMC 
treatments received  
Children aged 3-59 
months at cycle 1.  
2.87 
(2.49,3.24)  





Coverage of 4 cycles % received 4 treatments Children aged 3-59 








Coverage of 4 cycles by region:   




























Dalaba, Pita, Mamou, Faranah -  -  70.4% 
(61.4%,78.1%) 
533 
Adherence % received 3 doses at 
last cycle (if treated) 
Children aged 3-59 








Reach of SMC programme % who received at least 
one treatment 
Children aged 3-59 








Coverage of cycle 1 % treated at cycle 1 Children aged 3-59 








Coverage of cycle 2 % treated at cycle 2 Children aged 3-59 








Coverage of cycle 3 % treated at cycle 3 Children aged 3-59 
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Coverage of cycle 4 % treated at cycle 4 Children aged 3-59 








Treatment of older children Mean number of SMC 
treatments received 









Awareness of SMC dates % households heard 
date before last cycle 







LLIN use in children % slept under an LLIN 
last night 
Children 3-59 months 
who slept in the 








LLIN use (all ages) % slept under an LLIN 
last night  
All who slept in the 








ACCESS (% of population) % that could sleep 
under LLIN (if 2/net)  
All who slept in the 








% households with an LLIN  % households with an 
LLIN  







ACCESS (% households) % household with a LLIN 
for every two members 
All households, all who 








Caregiver knowledge about 
SMC 




1135 7.0  
(6.5,7.6) 
1068 6.6  
(6.3,6.9) 
1521 
Reported CHW adherence 
to guidelines 
Mean score out of 8 Carers of a child who 
received SMC last cycle 
6.07  
(5.41,6.72) 
1135 7.6  
(7.3,7.8) 
1068 6.3  
(6.0,6.6) 
1127 
SMC directly observed % of first doses 
administered or 
observed by CHW 
Children 3-59 months 









Interval between cycle 1 
and cycle 2 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
34 days 1192 34 days 1261 33 days 2447 
Interval between cycle 2 
and cycle 3 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
36 days 1150 32 days 1231 32 days 2447 
Interval between cycle 3 
and cycle 4 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
29 days 969 33 days 686 32 days 2447 
SMC card at survey % of children with SMC 
card 
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EXECUTIVE SUMMARY and RECOMMENDATIONS 
Background:  
In 2020, SMC distribution in Guinea was expanded to include the prefectures of Pita, Mamou, 
Dalaba, Faranah, SMC was therefore implemented in 17 prefectures, which include 50% of 
the population outside the city of Conakry and 60% of the land area of the country. In 2020 
the COVID-19 pandemic, and the presidential elections in Guinea, could potentially have 
affected SMC campaigns. It was therefore important to evaluate coverage of SMC given these 
challenges and the much wider area of implementation. 
 
Seasonal Malaria Chemoprevention (SMC) was introduced in Guinea in 2015 for children aged 
3 months to 5 years, over 4 months of the year, in 6 prefectures, and was scaled-up gradually 
to 8 prefectures in 2016, and 10 in 2017 and 13 prefectures in 2018. SMC gives children a high 
level of personal protection from malaria. Evaluation of SMC programmes by the ACCESS-SMC 
project showed substantial reductions in malaria cases and malaria deaths in children, 
associated with introduction of SMC [1]. High coverage of monthly cycles is needed to 
maximise the impact of this intervention. In 2020, four cycles of SMC were delivered in the 
prefectures of Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, Tougué and Dinguiraye, with 
support from PMI, and in Siguiri, Mandiana, Dabola, Kouroussa, Kankan, Pita, Dalaba, Mamou 
and Faranah prefectures, supported by the Global Fund, in July, August, September and 
October. This survey was conducted to assess coverage of SMC and use of long-lasting 
insecticide-treated bednets (LLINs) in 2020 in the 17 prefectures.  
 
The survey took place from 3rd Dec to 22nd December 2020.  All children aged 3 months to 7 
years were included in order to determine coverage in the target age group (aged at least 
3months at the time of treatment, and aged not more than 59 months at cycle1) and to 
determine the proportion of children above the recommended age limit who received 
treatment. Caregivers were interviewed about SMC treatments, dates of treatments were 
recorded from the SMC card, and SMC registers were checked to verify SMC treatments for 
children who did not have a card for inspection during the survey and for subset of children. 
In addition, all persons who slept in the household the night before the survey were listed, all 
bednets owned by the household were also listed and inspected, and for each person, the net 
they slept under, if any, was noted.  
 
A total of 2,447 children eligible to receive 4 treatments were surveyed in 90 clusters. A total 
of 1374/1521 of households agreed to participate, a response rate of 90.3%. 465 children too 
old to be eligible for SMC, were also surveyed. Use of LLINs was assessed for a total of 7,028 
household members. 
Administrative data:  
A total of 4.4 million treatments were administered in 2020 over four cycles to a target 
population of 1.1milliion children. The mean number treated per cycle was 1,088,832 (101% 
of target), and the number that received 4 cycles was 956,559 (89% of the target population). 
These administrative estimates compare with the survey estimate of the percentage of 
eligible children who were reached, 82.4%, and the percentage of children who received 4 
cycles, 70.8% of eligible children. Administrative estimates over-estimate coverage due to 
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errors in the target population size, population movement, and inclusion of treatments 
administered to ineligible children.  
 
In cycle 1, an average of 5.8 per 1000 infants and 3.3 per 1000 children were unwell during 
the SMC visit and were referred. In cycle 4, the average proportion referred was 1.3/1000 in 
infants and 0.5/1000 in children. 
 
In cycle 1, the proportion of children who vomited and were given a replacement dose was 
13/1000 among infants 3-11 months and 4.7/1000 among children 12-59 months. The 
proportion who vomited decreased in successive cycles, in cycle 4 in total 6.9/1000 infants 
and 1.8/1000 children vomited and were given a replacement dose.  
 
In cycle 1, there were 3276 refusals, a rate of 3 per 1000 children seen. Most of the refusals 
were in Siguiri prefecture, where the rate of refusal was 15/1000 in cycle 1.  
 
SMC coverage in 2020:  
Children aged 3 to 59 months at the time of cycle 1 were eligible to receive SMC four times, 
and should receive all of these treatments to maximise their protection. Overall, the 
percentage of eligible children who received SMC was 78.2% in cycle 1, 79.9% in cycle2, 77.4% 
in cycle3, and 77.2% in cycle 4. Children who did not receive SMC in cycle 1 tended not to 
receive SMC in later cycles. A total of 17.6% of children did not receive any SMC treatment in 
2020, and 70.8% of eligible children received four monthly treatments. SMC was equitable 
with similar coverage in boys and girls and according to caregiver wealth based on ranking 
according to household assets. In the four prefectures which implemented SMC for the first 
time in 2020 (Pita, Mamou, Dalaba and Faranah), a target population of 240,000, the average 
coverage per cycle was 80.4%, with 70.4% of children receiving all four cycles. The most common 
reasons the caregivers gave for their child not receiving SMC at cycle 4, were that the child or 
caregiver was away at the time of the campaign in their village. 
 
Siguiri prefecture accounted for the largest number of treatments administered, but the 
lowest coverage. This suggests the target population in Siguiri may be significantly larger than 
has been estimated.  
Timing of SMC cycles:  
Cycle 1 took place in July, cycle 2 in August, cycle 3 in September and cycle 4 in October. The 
median interval between treatments, based on dates recorded on SMC cards, was 33 days 
between cycle 1 and cycle 2, and 32 days between cycle 2 and 3, and 32 days between cycles 
3 and 4. These intervals should be reduced to 28 days. Cases will increase in the 5th week as 
protection wanes rapidly after 4 weeks. 
Assessment of SMC status in the survey:  
Of children eligible for four SMC treatments who were surveyed, 16.6% had not received an 
SMC card, 83.4% had received a card, and of those who received a card, 71.5% retained the 
card, so that during the survey a total of 59.6% of children had a card available for inspection. 
If the child did not have a card, registers were checked. SMC status could be verified using 
either card or register, for a total of 79% of eligible children.   
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For those children in the survey who had an SMC card and were found in the register, 
agreement between the card and register was 66%. Where there was disagreement, there 
tended to be more treatments in the register than on the card, suggesting that CHWs may 
not always record treatments on the card consistently.  
Awareness of SMC campaigns:  
Caregivers need to know the day when SMC will be distributed in their area in order to ensure 
they are available on that day. Overall, public information campaigns appeared successful, 
93.6% of households were aware of SMC and 92.1% said they knew in advance the date of 
the last campaign. 
Caregiver knowledge about SMC:  
Caregivers were asked if they understood key aspects of SMC, they scored 66% overall on a 
10-point questionnaire. Most caregivers (77%) knew that SMC is used to prevent malaria and 
most (76%) knew that there are 2 tablets to be taken on the first day and one on each of the 
next two days (85%). However there was a widespread view that SMC drugs could be used 
for treatment if there was someone unwell in the household (only 36% of caregivers gave the 
correct response, that SMC drugs should not be used in this way), and only 63% of caregivers 
appreciated the importance of completing the 3-day course of treatment 
Community Health Worker (CHW) adherence to SMC guidelines as reported by caregivers:  
CHW’s should check the child’s age, and before administering the treatment should ask about 
illness and refer the child if they are unwell, and should check the child has not had severe 
side effects to SMC before. They are also trained to explain to the caregiver how to administer 
the amodiaquine tablets on the next two days, and to advise caregivers about potential side 
effects and to bring the child to a health worker if they are become unwell after SMC. 
Caregivers of children who had received SMC, reported that the CHW generally followed 
these guidelines correctly, but were less likely to check for previous side effects to SMC or 
other medicines.  
Administration of SMC:  
In 99.5% of treated children, the first dose was directly observed, either administered by the 
CHW (87.4%) or by the caregiver in the presence of the CHW (12.2%). In a small number of 
cases, (0.5% of children) the blister pack was left with the caregiver to administer later, not 
observed by the CHW. Reported adherence to the unsupervised doses of amodiaquine was 
very high. Of eligible children treated at cycle 4, caregivers reported that 96.8% received all 
three daily doses.  
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Treatment above the age limit:   
Children who are above 5 years of age at the time of the first SMC cycle, should not receive 
SMC. The dose has been calculated according to age and if older children are given the blister 
pack intended for the 12-59-month group, they may be under-dosed, this can select for 
resistance as parasites are exposed to sub-therapeutic doses of SMC drugs. 465 children 
6years and above were surveyed. Only 6.3% were reported to have received an SMC card, 
and 5.2% received SMC in each cycle.  
Bednet use:  
In the 2018 survey, 30.2% of children slept under a LLIN the night before the survey. In the 
2019 survey, following a mass distribution campaign, this increased to 86% of children. In the 
2020 survey, this had fallen to 66% of children under 5 slept who under an LLIN the night 
before the survey. Coverage was lower in Siguiri prefecture than in other areas. LLIN use was 
lower than in 2019, in all age groups and in all areas, the reduction was greatest in Siguiri and 
Mandiana.  
 
Children above the age of 5 were less likely to use an LLIN than children under 5. This drop  
in LLIN use above the age of 5 was more marked in some areas than others. The percentage 
of the 5-9 age group that slept under an LLIN was only 54%.  
 
Of 1,377 households surveyed, 73.5% had at least one LLIN and 23.4% had one LLIN for every 
2 persons. This compares with 89.8% had at least one LLIN and 36.8% had one LLIN for every 
2 persons in the household, in 2019. Access to a LLIN, the percentage of the population who 
could sleep under a LLIN if there were two people per net, was 25.4% in 2018. This increased 
to 68.2% in 2019, and decreased 52.3% to the current survey. 61% of household members 
slept under an LLIN. 
 
COVID-19: 
Caregivers were asked if they had experienced three or more of the following symptoms at 
the same time in the past 6 months: fever, cough, sore throat, shortness of breath, fatigue, 
aches and pains, headaches, runny nose, and if they had any of these symptoms now. A total 
of 0.3% said they had 3 or more of these symptoms now and 2.9% said they had 3 or more 
symptoms together at some time in the previous 6 months. A total of 7 people (0.6%, 95%CI 
0.2%,1.6%) said they had been tested for COVID-19. A total of 4 people (0.2%, 95%CI 
0.09%,0.6%) said they thought they had been in contact with someone who had tested 
positive. 
Recommendations:  
1. SMC during 2020:  
High SMC coverage has been maintained in 2020 despite the challenges of delivery during the 
COVID-19 pandemic, and high coverage was achieved in the four prefectures where SMC was 
introduced for the first time in 2020.  
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2. LLIN use in children who have stopped receiving SMC:  
There was a marked increase in the use of LLINs following the successful distribution 
campaign in 2019. LLIN use has decreased from 85% of children under 5, and 80% of the 
population (of all ages) who slept under a LLIN the night before the survey in 2019, to 66% of 
children and 61% of all ages. There was a notable dip in LLIN use in children above the age of 
5 yrs, with the lowest LLIN use in children aged 7yrs (45%). This is of concern, children who 
stop receiving SMC at age 5 need to be protected with an effective net. Specific efforts need 
to be made to ensure high levels of LLIN use in this age group.  
3. Number of SMC cycles:  
In many of the areas where SMC is currently being implemented, more than 4 cycles of SMC 
are needed to provide protection throughout the high-risk period. Increasing the number of 
cycles where appropriate is now supported by WHO. In the 2011 WHO review, areas with 
highly seasonal malaria transmission corresponded approximately to areas where 60% of 
annual rainfall fell in 3 consecutive months. By this criterion, based on 2020 rainfall patterns 
from CHIRPS [18], all areas of Guinea would be eligible except for the southern prefectures of 
Yemou, Lola, Nzerekore, Macenta, Gueckedou,and Kissidougou. Within areas with highly 
seasonal rainfall, malaria seasonality can vary depending on distance to water bodies and 
river flood plains [11]. Seasonality in malaria case reports is also influenced by diagnostic 
accuracy, and by seasonal population movement. In most prefectures where SMC is currently 
implemented, increasing the number of cycles would be expected to increase the proportion 
of annual burden included in the SMC period by about 10% (Annex C). Longer-term planning 
should also include how the malaria vaccine will be used in Guinea and combined with SMC 
in the most effective manner [22] if, as is anticipated, WHO recommends wider use of the 
vaccine. 
4. Monitoring of the efficacy of SMC  
Molecular monitoring of SMC efficacy through the ACCESS-SMC project in 7 countries 
including Guinea in 2016 and 2018 showed that key mutations were uncommon but there 
was evidence of selection for resistance to SP. In Guinea, the monitoring site was Siguiri 
prefecture, in the general population the quintuple mutation associated with resistance to SP 
had a prevalence of 1.6% in 2016 and 6.1% in 2018, an increase of 4.4% (95%CI 1.4%-7.5%). 
Molecular monitoring should be repeated in the same sample locations to assess whether 
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BACKGROUND AND OBJECTIVES 
The Republic of Guinea is one of 17 high burden countries which, according to WHO 
estimates, accounted for more than 80% of deaths due to malaria worldwide in 2019 [1]. 
Malaria occurs year-round with a highly seasonal pattern in the north of the country. The 
main vectors are Anopheles gambiae, An. funestus, An. melas and An. arabiensis. WHO [1] 
estimated there were 3,792,217 cases of malaria and 8,180 deaths caused by malaria in 
Guinea in 2019 in a population of 12.8million. The estimated 2020 population is 13.1million 
in total including 2.1million children under 5 years of age [2]. Under-5 mortality was 
estimated to be 111 per 1000 live births in the 2018 DHS survey (over the 5-year period with 
midpoint 2016) [3], and 80.7 (for the 5-year period with midpoint 2018) in the UN 
projections [2].  
 
Seasonal Malaria Chemoprevention (SMC) was introduced in Guinea in 2015. SMC involves 
the administration of a treatment course of sulfadoxine-pyrimethamine plus amodiaquine 
once a month to children aged 3–59 months during the high risk period each year to prevent 
malaria [4], recommended by WHO initially for up to 4 months of the year but as of 2021, for 
up to 5 months. Evaluation of the introduction of SMC in 7 countries, including Guinea, 
through the ACCESS-SMC project, showed that despite the challenges of door-to-door 
delivery, SMC has been highly effective in reducing malaria cases and malaria deaths in 
children [5,6].  
 
In Guinea, SMC was introduced initially in 6 prefectures, scaling up to 13 prefectures by 2018 
(Table 1). A survey in the 13 prefectures with SMC in 2018 showed that 79% of children 
received SMC at least once, and 61% received four treatments [7]. There were geographical 
variations, with the lowest coverage in the prefecture of Siguiri. Use of bednets (LLINs) was 
low, only 30% of children slept under an LLIN the night before the survey, 40% of households 
owned an LLIN, 13% of households had one LLIN per 2 persons, and 25% of the population 
had access to a LLIN. In 2019 [8], there were marked improvements in use of LLINs, 85.7% of 
children slept under an LLIN, 89.8% of households owned a LLIN, 36.8% of households had 
one LLIN per 2 persons, and 68.2% of the population had access to a LLIN. In the 5 prefectures 
where 4 cycles of SMC were delivered in 2019, 58% of children received four treatments, 
(though coverage was again lower in the prefecture of Siguiri). 
 
In 2020 the COVID-19 pandemic threatened to disrupt malaria control activities. WHO 
produced guidelines for adapting malaria control measures [9] and RBM published specific 
operational guidance for SMC [10] including maintaining social distance during training and 
delivery, use of face masks and hand washing, and advice that the first dose each month 
should be given by the caregiver, observed by the distributor.  
 
The present survey was conducted in 17 prefectures at the end of the 2020 transmission 
season to determine SMC coverage and use of LLINs. The survey aimed to determine the 
percentage of children who received SMC in each cycle, the percentage who received the full 
four treatments, the adherence to the SMC regimen, and the use of insecticide-treated 
bednets by all household members, and to ask caregivers of children who did not receive four 
treatments, the reasons their children missed SMC treatments.  
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Description of Seasonal Malaria Chemoprevention  
SMC involves administration of a course of treatment of sulfadoxine-pyrimethemine plus 
amodiaquine over three days, once per month for four months of the malaria transmission 
season, to prevent malaria illness. Children aged at least 3 months and less than 5 years of 
age are eligible to receive SMC, however children who were under 5 years of age at the first 
month continue to receive all four monthly treatments even if they reach the age of 5 during 
the 4-month period of SMC distribution. Each monthly treatment consists of a dose of 
sulfadoxine-pyrimethamine and a dose of amodiaquine, administered on the first day, and a 
dose of amodiaquine on each of the next two days. The drugs are distributed by community 
health workers (CHWs) who visit door to door to administer the first day’s doses and leave 
the blister pack with the caregiver with instructions to administer the remaining amodiaquine 
doses on each of the next two days. CHWs check the age of the child and select the 
appropriate blister pack (lower dose for infants, higher dose for children 12-59 month), ask 
about allergies to SMC drugs, check whether the child has been given sulfadoxine-
pyrimethamine or amodiaquine or any sulfa-containing antibiotic in the last 4 weeks, and 
check if the child has a fever. Children are eligible if they do not have known allergies to the 
drugs, have not been given amodiaquine of sulfa-containing medication in the last 4 weeks, 
and are not unwell. Children who are unwell should be referred to the nearest health centre 
where they can be appropriately treated, including treatment with an ACT if they have 
malaria. If they do not have malaria, they may receive SMC at the clinic. CHWs should also 
remind caregivers to bring the child to the health centre if the child becomes unwell at any 
time after taking SMC, and that the child can still develop malaria and so the guidance to seek 
treatment promptly in the case of fever should continue to be followed, and all household 
members should sleep under a treated bednet. Each course of SMC treatment provides about 
90% protection from malaria for 28 days so that four treatments one month apart can provide 
a high degree of personal protection for 4 months. Introduction of SMC with high coverage 
has been found to reduce the incidence of malaria, severe malaria, and malaria deaths, 
substantially. To maximise the impact of the intervention, it is important that the first SMC 
cycle is timed to start at the beginning of the main transmission period; cycles should take 
place at monthly intervals; high coverage of 4 monthly treatments should be achieved; and 
caregivers should ensure children adhere to the daily regimen each month. Insecticide treated 
bednets should continue to be used, SMC should be an additional measure not a substitute 
for bednets. The survey therefore assessed bednet use by children and other members of the 
household. 
Scaling-up of SMC in Guinea  
SMC was introduced in Guinea in 2015, with four monthly cycles, in 6 prefectures with a target 
population of 210,107 children. The area covered was increased to 8 prefectures in 2016, 10 
in 2017, and 13 in 2018. The same 13 prefectures were included in 2019, (three cycles in 8 
prefectures supported by PMI and four cycles in the 5 prefectures supported by the Global 
Fund). In 2020 the target area was expanded to 17 prefectures, for 4 cycles (Tables 1 and 2 
and Figure 1), with a target population of 1,077,467 children, an increase of about 32% 
compared to the target number in 2019. Siguiri and Kankan are the largest prefectures 
together accounting for about one quarter of the target population of children in the 17 
prefectures. 
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Table 1: Expansion of SMC in Guinea 2015-2020 
Prefecture 2015 2016 2017 2018 2019 2020 
Dinguiraye X X X X X X 
Gaoual X X X X X X 
Koubia X X X X X X 
Koundara X X X X X X 
Mali X X X X X X 
Tougue X X X X X X 
Mandiana X X X X X 
Siguiri 
 
X X X X X 
Labe 
  
X X X X 
Lelouma 
  
X X X X 
Dabola 
   
X X X 
Kankan 
   
X X X 
Kouroussa 
  
X X X 
Pita     X 
Dalaba     X 
Mamou     X 
Faranah     X 
Target population 210,107 438,123 591,071 825,994 818,502 1,077,467 
 
 
The indicators related to delivery of SMC, from 2015 to 2020, are summarised in Table 2 
below. The estimated percentage of children who received four SMC treatments was 57% in 
2015 and 73% in 2016 and 63% in 2017 and 61% in 2018 and 41% in 2019 (lower because the 
fourth cycle was not implemented in PMI areas in 2019).   
 
Table 2: SMC delivery in Guinea 2015-2020 



















2015 6 210,107 805,131 80% 94% 57% 197,501 119,761 
2016 8 438,123 1,750,224 88% 96% 73% 420,598 319,830 
2017‡ 10 591,071 2,303,709 73% 79% 63% 466,946 372,375 
2018 13 825,994 3,356,780 72% 79% 61% 655,013 501,378 
2019 13  818,502† 2,986,364 72% 86% 41% 699,819 338,860 
2020 17 1,077,467 4,355,326 78% 82% 71% 888,355 762,743 
*The target population multiplied by the estimate proportion of children who received at least one SMC treatment. #The 
target population multiplied by the proportion of children who received four treatments.
 †
Population updated based on 
bednet campaign estimates. 
‡
Sampling for the 2015 and 2016 surveys was based on the 1996 census, whereas for the 
surveys conducted since 2017, population data from the 2014 census were used. The earlier census did not reflect the 
increased population in mining areas. The apparent decrease in the percentage of children who received SMC in 2017 reflects 
a more representative sampling frame for the selection of survey villages, which included mining areas in Siguiri where SMC 
has been most challenging. These areas were not included in the 2016 survey. 
  
18                                                                 Seasonal Malaria Chemoprevention Coverage in Guinea in 2020 
 
  
Figure 1: A - Scale-up of SMC 2015-2018.  B- Population distribution in SMC areas 
 




B: Survey locations and distribution of population in SMC areas  
Source for spatial population data: Worldpop (2019) 
 
 




SMC target population in 2020 
The total estimated population of children to be treated was 1,077,465 (Table 3). The 2014 
census estimates of the population were used for probability proportional to size selection of 
survey clusters and for calculation of survey weights.  
 

















Siguiri 162,041 15% 157,639 179,333 708,506 963,394 
Kankan 112,777 26% 109,713 105,578 963,264 578,195 
Mandiana 80,344 33% 78,161 77,431 335,921 418,559 
Mamou 76,244 40%   316,869 352,298 
Labe 75,995 47% 76,221 73,786 318,938 349,419 
Mali 73,099 54% 70,937 68,741 290,614 322,365 
Faranah 66,998 60%   280,962 342,615 
Pita 66,613 66%   274,468 293,646 
Kouroussa 64,191 72% 62,446 64,442 545,212 327,632 
Gaoual 46,996 77% 47,103 45,819 196,190 216,491 
Dinguiraye 46,300 81% 46,804 45,797 199,465 222,018 
Lelouma 44,907 85% 43,473 42,084 163,069 175,804 
Dabola 43,319 89% 42,142 41,734 181,129 212,804 
Dalaba 31,951 92%   132,677 132,431 
Koundara 31,122 95% 31,184 30,335 131,388 148,324 
Tougue 30,708 98% 29,468 28,484 125,405 127,467 
Koubia 23,860 100% 23,212 22,430 101,293 102,469 
TOTAL 1,077,465  818,503 825,994 5,265,370 5,285,930 
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METHODS 
The survey was conducted from 3 to 22 Dec 2020. Ninety settlements were selected from 17 
prefectures where SMC was implemented in 2020 (Figure 1), with probability proportional to 
population size based on the 2014 General Population and Housing Census (RGPH), and in 
each selected settlement, area sampling was used, whereby the settlement was divided into 
segments, one segment chosen at random, and all households in the selected segment 
included in the survey. In clusters which were too large to segment easily, the total area was 
estimated by taking GPS locations around the perimeter of the inhabited area. A single 
location was then chosen, by randomly generating an x and y coordinate within the 
settlement (this was done independently of the survey team and the location sent to them 
by email). Interviewers surveyed houses around this point, recording the GPS location of each 
dwelling, and continuing outwards, without missing any dwellings, until 20 children had been 
included. In the final dwelling, all children eligible for the survey were included so the final 
sample size for the cluster could exceed 20.  
 
Teams were provided with face masks, aprons, sanitiser gel and soap, and were trained to 
maintain social distance as far as possible and to wash hands before and after each household 
visit. 
 
In each household, the aims of the survey and the nature of the questions were explained 
and signed consent (on paper consent forms) was sought from the head of the household. 
Verbal consent was then sought from each caregiver and documented electronically.  
 
Caregivers of children were asked about SMC treatments their child had received, SMC record 
cards were inspected and photographed, and SMC registers, borrowed from the local health 
centre, were checked to find the child’s entry using the ID number on the SMC card or, if the 
card was not available, using the child’s name and caregiver’s name. All children aged 3 
months to 7 years were included in order to determine coverage in the target age group (aged 
at least 3months at the time of treatment, and aged not more than 59 months at cycle1) and 
to determine the proportion of children just above the recommended age limit who received 
treatment. In addition, all persons who slept in the household the night before the survey 
were listed, all bednets owned by the household were also listed and inspected, and for each 
person, the net they slept under, if any, was noted.  
 
Registers were available for all clusters except one (Franwalia in Siguiri, where the team were 
not able to access the store in the local health centre where the register was kept due to 
absence of the head of the centre). 
 
When caregivers reported more SMC treatments than were recorded on the SMC card, it is 
plausible that treatments were received but not recorded on the card by the community 
health worker, or that caregivers did not accurately recall the exact number of treatments. In 
the cases where the caregiver said the child had not received any SMC, but there were several 
SMC treatments recorded on the card, it is possible that the respondent was not the same 
person that cared for the child during the SMC campaigns, or that cards for different children 
had been swapped during SMC delivery. Overall however, there was a high level of agreement 
between recall and card, as has been observed in previous surveys.  
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In most of the cases where there was disagreement between card and register, and between 
caregiver recall and the register, the number of treatments was greater according to the 
register, that is, there were more treatments in the register than according to either the card 
or the caregiver. This could occur if health workers enter treatments in the register but omit 
to record on the card. It is possible registers are completed before children have been treated, 
and then the child is not treated, but we have no independent evidence of this happening. 
There could also be linkage errors, the wrong record in the register being used.  
 
In this report, we have used a combination of recall, card and register; the child was assumed 
to have been treated in a particular month if there was a treatment recorded on the card 
(even if the caregiver disagreed), and if there was a record in the register (even if not on the 
card, or the caregiver disagreed). If the caregiver stated the child had been treated, but there 
was no record in the card, it was assumed the child had been treated but the treatment had 
not been recorded.  
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Training, piloting and data collection 
Training took place over 2 days, 26-27 November 2020. The training covered the use of the 
survey tools, understanding the questionnaires, and field methods. 26 participants 
participated in the training: 21 interviewers, 1 Global Fund staff, 2 supervisors,  and 2 trainers. 
The first day covered operation of tablet PCs, tablet settings, and the use of the data entry 
software, and comprehension and practice in the use of the data entry forms. The second day 
covered taking photographs of SMC cards, recording GPS coordinates, saving and finalizing a 
form, making corrections and field methods. Data collection was then piloted in the field on 
Dec 1-2, 2020, teams were trained in identifying segments of the survey villages, and 
administration of survey questionnaires. For the main survey, which started Dec 3 and ended 
on Dec 22 2020, survey staff were organised in 7 teams. 
 
Data management 
Data were collected using Android tablets (Nexus 7 (4 devices) and Samsung T285 Galaxy Tab 
A (17 devices)).  Software used was ODK.  The ODK form metadata are available from the 
authors.  The form used nested repeat structures to enable the capture of data at the 
household, caregiver and child levels – with linkage between the levels implemented directly 
through the ODK tool. The ODK aggregate server was based at the London School of Hygiene 
and Tropical Medicine.  The devices used strong encryption so that if devices were lost the 
data could not be seen by non-team members.  Encryption was also used on the aggregate 
server, and the only way to retrieve the meaningful data was by using suitably setup ODK 
Briefcase – which allowed the decryption of the data from the server.  The data were 
delivered as CSV files (in UTF 8 format).  These files were then inserted into spreadsheet 
workbooks (separate sheet for each level).  These spreadsheets were made available to 
members of LSHTM team and the data manager based in Guinea so that the data could be 
reviewed (for cleaning purposes) and for analysis. A separate MS Access version of the data 
sets was created, again using the source csv files, so that the images of the cards could also 
be reviewed against the data entered.  This was used to identify missing data from the cards. 
The MS Access database became the cleaned version of the database, and it was the source 
used for analysis.  The data were extracted from the Access database using MS PowerBI – 
which enabled the decoding of the data gathered into the meaningful labels (e.g. so Male and 
Female were generated, rather than 1 and 2), and the merging of the data from the different 
levels. All data sharing between teams was implemented using MyFiles – the secure sharing 




Layout of the results 
Results for the key indicators are presented overall (average value for all 17 prefectures), and for 
each of five areas defined as follows:  
Area 1 - prefectures which started SMC in 2015 (Gaoual, Koundara, Koubia, Mali, Dinguiraye, 
Tougué);  
Area 2 – prefectures which started SMC in 2016 (Mandiana and Siguiri)  
Area 3 – prefectures which started SMC in 2017 (Labé, Lelouma) 
Area 4 – prefectures which started SMC in 2018 (Dabola, Kouroussa, Kankan) 
Area 5 – prefectures which started SMC in 2020 (Pita,Dalaba,Mamou,Faranah) 
 
Areas 1 and 3 are supported by PMI and Areas 2,4 and 5, Global Fund.  
 
Estimates for each prefecture separately are also provided but for some prefectures the number 
of clusters is small and the survey is not designed to produce reliable estimates in these 
prefectures. 
 
95% confidence intervals are presented for the key indicators which show the degree of 






A total of 1,374 households participated in the survey (Table 4), 90% of all households visited. The 
location of the clusters is shown in Figure 1B. A total of 3398 children were included, of these 2447 
were aged 3-59 months at the time of cycle 1 and hence eligible to have received four SMC 
treatments. 465 children were aged 6-7 years when the survey was done and so were above 5 
years of age at the time of SMC cycle 1. 
 
Table 4: Response rates and the number of households, children and other household 
members surveyed: 
Households surveyed: No. of households %  
Agreed to participate 1374 90.3% 
No children of eligible age      81   5.3% 
Refused to participate        6   0.4% 
Unable to find someone to speak with/no access      60   4.0% 
TOTAL 1521   
Response rate by area:   
Dinguiraye Gaoual Koubia Koundara Mali Tougue 318 89.3% 
Labe Lelouma 159 62.9% 
Siguiri Mandiana 247 98.0% 
Dabola Kankan Kouroussa 438 97.5% 
Dalaba Pita Mamou Faranah 359 89.4% 
   
Children surveyed: No. of children  
Aged 3-59 months at cycle 1 (eligible for 4 SMC treatments) 2447  
Aged 5-6 years at survey   486  
Aged 6-7 years at survey (more than 5 years of age at cycle 1)   465  
TOTAL (3 months to 7 years at survey) 3398  
Children surveyed, by area: (eligible for 4 treatments)  
Dinguiraye Gaoual Koubia Koundara Mali Tougue 450  
Labe Lelouma 134  
Siguiri Mandiana 544  
Dabola Kankan Kouroussa 786  
Dalaba Pita Mamou Faranah 533  
Caregivers surveyed: 1497  
   
Slept in the household the night before, by age and gender:   
Age group Female Male 
0-4yrs 1,259 1,238 
5-9yrs 611 646 
10-14yrs 193 195 
15-19yrs 194 84 
20-24yrs 271 34 
25-29yrs 412 100 
30-34yrs 325 173 
35-39yrs 235 214 
>=40yrs 225 619 
Total 3,725 3,303 
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Timing of SMC cycles 
SMC treatments provide a high degree of protection for 28 days, after this time protection 
decreases rapidly. SMC cycles should therefore take place at intervals of 28 days (the first day of 
the cycle starting 28 days after the first day of the previous cycle), to ensure children remain 
protected. Cycle 1 took place in July, cycle 2 in August, cycle 3 in September and cycle 4 in October 
(Figure 4, Table 5). The median interval between treatments, based on dates recorded on SMC 
cards, was 33 days between cycle 1 and cycle 2, and 32 days between cycle 2 and 3, and 32 days 
between cycles 3 and 4 (Table 6, Figure 5). These intervals should be reduced to 28 days. Cases 
will increase in the 5th week as protection wanes rapidly after 4 weeks. 
Table 5: Planned timing of cycles: 
1 2 3 4 
3 Jul-7 Jul 5 Aug-9 Aug 5 Sep-9 Sep 1 Oct-5 Oct 
 7 Aug-11 Aug 7 Sep-11 Sep 9 Oct-13 Oct 
Dates from SMC cards:   
3 Jul-7 Jul 5 Aug-12 Aug 3 Sep-10 Sep 1 Oct-12 Oct 
 
Table 6: Median interval between treatments (min-max), in days, determined from dates SMC 
record cards  
Days 
Cycle 1 to cycle 2 33 
Cycle 2 to cycle 3 32 
Cycle 3 to cycle 4 32 





Figure 5: Interval between cycles 
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Retention of SMC cards 
Of 2447 children eligible for 4 SMC treatments who were surveyed, 16.6% did not receive an SMC  
card, compared with 12% in 2019 and 9% in 2018. 83.4% received a card (88% in 2019, 91% in 
2018).  Of those who received a card, 71.5% retained the card (76% in 2019, 69% in 2018). A total 
of 59.6% had a card available for inspection in the survey. 
 
Agreement between caregiver recall, the SMC card, and registers 
To assess the reliability of SMC status determined during the survey, the number of SMC 
treatments reported by the caregiver was compared with the number recorded on the SMC card 
(for those children who had a card for inspection in the survey), and, for a subset of children, the 
number recorded in the SMC register. Caregivers were asked about the number of treatments, 
before looking at the SMC card or register. Out of the 2447 children in the survey who were eligible 
for four treatments, a total of 1503 children had a card for inspection in the survey (Table 7). In all 
clusters but 1, an attempt was made to find entries in the SMC register for all children in the 
survey. This was possible for 438/944 (46%) children without a card. The survey estimate, based 
on caregiver recall, of the percentage of children who received SMC at least once, among those 
who did not have a card available for inspection at the survey, was 42%. Therefore the number 
found in registers is what we would have expected, bearing in mind that most children who did 
not receive SMC are not included in registers. Register entries were also found for some children 
who had an SMC card (885/1503, 59%) although this was not done for all children with a card. 
 
Table 7: Number of eligible children whose SMC status was confirmed by card and from 
registers 
  
Card seen No card Total 
Eligible for 4 treatments 1503 944 2447 





The percentage agreement between caregiver’s recall and SMC record card, with regard to the 
number of treatments, for the 1,503 children with a card, was 63% (compared with 83% in 2019). 
Of 251 children in Table 8 where the caregiver said the child had no SMC, for whom all but 2 had 
SMC marked on the card, 175 were found in the register, and of these 175, 169 had received SMC 
4 times according to the register, 1 had SMC 3 times, 4 had SMC twice and one had SMC once.  
Table 8: Agreement between recall and card, for children in the survey with an SMC card:  
Number of treatments on the SMC card 
 
 






      
0 2 26 18 14 191 251 
1 0 36 2 0 1 39 
2 0 24 32 6 13 75 
3 0 34 34 87 21 176 
4 2 58 66 46 790 962  
      
Total 4 178 152 153 1,016 1,503 
 
For those children who did not have an SMC record card, agreement between caregiver’s recall 
and the register, in the 438/944 children who could be found in registers, was 53% (Table 9).  
Table 9: Agreement between recall and register, for children without an SMC record card:  
Number of treatments in the SMC register 
 
 
0 1 2 3 4 Total 




      
0 0 1 1 9 129 140 
1 1 3 0 1 5 10 
2 0 1 11 5 6 23 
3 0 0 0 20 28 48 
4 0 1 7 10 199 217  
      
Total 1 6 19 45 367 438 
 
Children who did not receive SMC at all, will not be listed in registers (except those few who were 
seen by the CHW, entered in the register, but did not get SMC). Out of the 944 children who did 
not have a card, 438 were found in the register and 506 were not found in the register. Of the 506 
who were not found, 74% (374/506) did not receive SMC according to the caregiver, compared to 




For those that had a card and were found in the register, agreement between the card and register 
was 66% (Table 10). Where there was disagreement, there tended to be more treatments in the 
register than on the card, suggesting that CHWs may not always record treatments on the card. 
There were few cases where treatments were recorded on the card but not in the register. 
However, the survey team did not attempt to find register entries for every child who had a card 
so these data may not be representative. 
Table 10: Agreement between card and register: 
 
Number of treatments in the SMC register 
 
 
0 1 2 3 4 Total 
Number of  
treatments  
according  
to SMC card 
      
0 0 0 0 1 3 4 
1 1 13 9 24 98 145 
2 0 1 15 18 71 105 
3 0 1 2 28 58 89 
4 0 0 2 15 525 542  
      
Total 1 15 28 86 755 885 
 
 
The SMC card is a record and reminder for the caregiver, so it is important that it is completed. 
Caregivers may use the card to check if their child’s treatments are complete, they could then seek 
treatment at the health centre if they missed the door-to-door campaign. Training of CHWs should 
emphasise the importance of recording treatments on the SMC card as well as in the register, and 
the need to remind caregivers to use and retain the card.  
 
When caregivers reported more SMC treatments than were recorded on the SMC card, it is 
plausible that treatments were received but not recorded on the card by the community health 
worker, or that caregivers did not accurately recall the exact number of treatments. In the cases 
where the caregiver said the child had not received any SMC, but there were several SMC 
treatments recorded on the card, it is possible that the respondent was not the same person that 
cared for the child during the SMC campaigns, or that cards for different children had been 
swapped during SMC delivery. Overall however, there was a high level of agreement between 
recall and card, as has been observed in previous surveys.  
 
In most of the cases where there was disagreement between card and register, and between 
caregiver recall and the register, the number of treatments was greater according to the register, 
that is, there were more treatments in the register than according to either the card or the 
caregiver. This could occur if health workers enter treatments in the register but omit to record 
on the card. It is possible registers are completed before children have been treated, and then the 
child is not treated, but we have no independent evidence of this happening. There could also be 




In this report, we have used a combination of recall, card and register; the child was assumed to 
have been treated in a particular month if there was a treatment recorded on the card (even if the 
caregiver disagreed), and if there was a record in the register (even if not on the card, or the 
caregiver disagreed). If the caregiver stated the child had been treated, but there was no record 




Awareness about the SMC campaign 
Caregivers should be to be aware of the purpose of the SMC programme and need to know the 
day when SMC will be distributed in their area in order to ensure they are available on that day. 
The survey asked one caregiver in each household if the household was aware about SMC and, for 
the most recent cycle if they knew in advance the date the health workers would come. Overall, 
93.6% of households were aware of the SMC campaign and 92.1% said they knew in advance the 
date of the campaign (Table 11).  
 
Table 11: Public awareness about SMC: the percentage of households that were aware of the 
SMC programme, and the percentage that heard the last campaign date in advance. 
 
Area % households aware 
of SMC (95%CI) 
% households who 
heard date of last cycle 
in advance (95%CI) 
Dinguiraye, Gaoual, Koubia,  
Koundara, Mali, Tougue 95.1% (91.2%,97.3%) 94.7% (89.6%,97.4%) 
Labe, Lelouma 98.4% (92.7%,99.7%) 96.7% (92.3%,98.6%) 
Siguiri, Mandiana 81.5% (68.6%,89.9%) 79.1% (64.1%,89.0%) 
Dabola, Kankan, Kouroussa 98.9% (97.5%,99.6%) 98.4% (96.5%,99.3%) 
Pita,Mamou,Dalaba,Faranah 93.2% (87.3%,96.5%) 90.9% (83.0%,95.3%) 




The most common sources of information about campaign dates were health workers, friends and 
neighbours, criers, the radio, and the mosque or church (Table 12, Figure 6). Radio messages 
reached about 45% of households. 

























Dinguiraye, Gaoual, Koubia,  
Koundara, Mali, Tougue 88.5% 37.4% 29.0% 0.0% 36.6% 1.2% 40.9% 1.4% 
Labe, Lelouma 31.1% 64.7% 37.2% 5.2% 60.7% 8.1% 36.0% 0.0% 
Siguiri, Mandiana 63.1% 59.2% 56.7% 0.0% 46.3% 2.7% 46.0% 3.3% 
Dabola, Kankan, Kouroussa 80.1% 61.7% 60.0% 5.3% 21.3% 3.4% 50.6% 12.7% 
Pita,Mamou,Dalaba,Faranah 39.9% 59.5% 41.3% 10.1% 66.7% 4.0% 50.7% 2.2% 
Total 63.4% 56.0% 45.5% 4.7% 44.6% 3.5% 46.3% 4.7% 
 




Characteristics of caregivers   
The caregiver was usually the child’s mother. 24% of caregivers looked after one child under the 
age of 5 years, 41% two children under 5, and 35% three or more children under 5. When asked 
how long they had been resident in the area, almost all (>99%) said they had lived there for at 
least 6 months. Only 39% of caregivers had had any formal education (Koranic or other) (Table 
13).  
Table 13: Characteristics of caregivers 
Characteristic Categories % 
Gender Male 2.1%  
Female 97.9% 
Relationship to child Parent 95.5%  
Sister/Brother 0.1%  
Aunt/Uncle 0.5%  
Grandparent 3.8%  
Neighbour 0.1%  
Other 0.1% 
Resident <6months 1.0%  
6months+ 99.0% 
No. of children <5yrs in their care 0 0.1%  
1 24.2%  
2 41.0%  
3 22.8%  
4 8.6%  
5 2.2%  
6 0.7%  
7 0.4% 
 8 0.0% 
 9 0.1% 
Any education None 61.1%  
Any formal/Koranic education 38.9% 
Years of education None 60.7%  
1-5yrs 23.7%  
6-10yrs 12.2%  
11+yrs 3.4% 
Marital status Unmarried 0.8%  
Married 96.1%  





Caregivers’ knowledge about SMC  
Caregivers were asked if they understood key aspects of SMC, they scored 66% overall on a 10-
point questionnaire (Table 14, 15). Most caregivers (77%) knew that SMC is used to prevent 
malaria and most (76%) knew that there are 2 tablets to be taken on the first day and one on each 
of the next two days (85%). However there was a widespread view that SMC drugs could be used 
for treatment if there was someone unwell in the household (only 36% of caregivers gave the 
correct response, that SMC drugs should not be used in this way), and only 63% of caregivers 
appreciated the importance of completing the 3-day course of treatment (Table 16, 17).  
Table 14: Caregivers’ knowledge about SMC:  
Question Correct 
response 
1 For how many months should the child take SMC 4 
2 SMC is given to prevent malaria Yes 
3 SMC can prevent other diseases No 
4 How many tablets should the child take on the first day? 2 
5 How many tablets should the child take on the second day? 1 
6 How many tablets should the child take on the third day? 1 
7 The child should swallow all the medication Yes 
8 I can give the tablets to someone else who is unwell No 
9 The child should complete the 3-day course of treatment Yes 
10 I should take the child to the health centre if unwell after SMC Yes 
Maximum score: 10 
 
Table 15: Caregivers’ knowledge scores on SMC and adherence to guidelines by CHW: 
Area 
Average caregiver  
knowledge score  
(out of 10) (95%CI) 
Average CHW score  
for adherence to  
guidelines (out of 8) (95%CI) 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 7.6 (7.0,8.3) 7.4 (6.9,7.8) 
Labe, Lelouma  5.6 (4.9,6.4) 6.2 (5.7,6.6) 
Siguiri, Mandiana 6.1 (5.5,6.6) 5.7 (4.7,6.7) 
Dabola, Kankan, Kouroussa 6.9 (6.6,7.3) 5.5 (4.9,6.2) 
Pita,Mamou,Dalaba,Faranah 6.5 (5.9,7.1) 6.6 (6.3,7.0) 






Table 16: Caregiver knowledge, % correct answers to each question 
 % correct 
Question 2018 2019 2020 
For how many months should the child take SMC (4) 59.9% 61.1% 49.7% 
SMC is given to prevent malaria  82.0% 83.5% 77.3% 
SMC can prevent other diseases (correct answer No) 68.9% 70.2% 67.1% 
How many tablets should the child take on the first day? (2) 79.4% 80.9% 76.2% 
How many tablets should the child take on the second day? (1) 82.8% 84.3% 84.5% 
How many tablets should the child take on the third day? (1) 82.8% 84.3% 85.0% 
The child should swallow all the medication (Yes) 67.7% 68.9% 69.0% 
I can give the tablets to someone else who is unwell (No) 43.7% 44.4% 36.4% 
The child should complete the 3-day course of treatment  60.9% 61.7% 63.3% 
I should take the child to the health centre if unwell after SMC 62.3% 63.4% 54.8% 
 
 


















For how many months  
should the child take SMC 52% 50% 21% 62% 53% 
SMC is given to prevent malaria 83% 60% 74% 83% 80% 
SMC can prevent other diseases 86% 44% 93% 67% 54% 
How many tablets should the child 
take  
on the first day? 79% 60% 67% 93% 74% 
on the second day? 86% 60% 91% 95% 84% 
on the third day? 86% 60% 92% 96% 85% 
The child should swallow  
all the medication 82% 60% 58% 76% 65% 
I can give the tablets to someone 
 else who is unwell 58% 53% 21% 7% 43% 
The child should complete  
the 3-day treatment 78% 58% 48% 64% 64% 
I should take child to the health  
centre if unwell  74% 59% 42% 52% 49% 
   
36 
 
Community Health Worker adherence to SMC guidelines, as reported by 
caregivers 
CHW’s should check the child’s age, and before administering the treatment should ask about 
illness and refer the child if they are unwell, and should check the child has not had severe side 
effects to SMC before. They are also trained to explain to the caregiver how to administer the 
amodiaquine tablets on the next two days, and to advise caregivers about potential side effects 
and to bring the child to a health worker if they are become unwell after SMC. Caregivers of 
children who had received SMC, reported that the CHW generally followed these guidelines 
correctly, but were less likely to check for previous side effects to SMC or other medicines (Table 
18, 19).  
 
Table 18: CHW adherence to guidelines 
 
Action % of caregivers who reported that 
the CHW performed the action at 
the last visit: 
  2017 2018 2019 2020 
1 Check the child's age 100.0% 80.1% 99.7% 98.0% 
2 Explain how to administer tablets 99.6% 79.8% 99.6% 99.2% 
3 Check for illness or fever 98.9% 79.6% 99.1% 91.9% 
4 Explain the common side effects of SMC drugs 97.0% 75.7% 94.7% 74.6% 
5 Advise to bring the child to the health centre if they are unwell 97.0% 77.5% 96.6% 76.0% 
6 Ask if the child had taken other medicines in the last 4 weeks 95.8% 71.1% 89.2% 71.5% 
7 Ask if the child had side effects to SMC before 92.9% 70.1% 88.1% 57.4% 
8 Ask about allergies to medicines 91.7% 72.8% 90.9% 62.6% 
 





































Check the child's age 99.2% 100.0% 98.9% 95.6% 98.2% 
Explain how to administer tablets 99.3% 100.0% 99.3% 99.1% 98.9% 
Check for illness or fever 90.9% 100.0% 84.7% 90.5% 94.3% 
Explain the common side effects of SMC drugs 90.8% 96.9% 54.5% 51.3% 86.5% 
Advise to bring the child to the health centre if they are unwell 90.6% 76.2% 56.4% 62.2% 87.7% 
Ask if the child had taken other medicines in the last 4 weeks 94.3% 41.0% 75.8% 66.0% 70.3% 
Ask if the child had side effects to SMC before 84.5% 41.0% 50.3% 44.7% 60.0% 




SMC administration at the last cycle before the survey (cycle 4) 
Caregiver’s recall is likely to be most accurate about the last SMC treatment, so questions about 
administration of SMC drugs were asked specifically about SMC treatment at the fourth cycle.  
 
In 99.5% of treated children, the first dose was directly observed (administered by the CHW 
(87.4%) or by the caregiver in the presence of the CHW (12.2%)), Table 20. A small number of 
children (0.2%) received the first dose from the caregiver later, not observed by the CHW. And for 
0.3% of children, the caregiver received the blister pack but did not administer the first dose (Table 
21). 
 
Table 20: Percentage of SMC treatments directly observed (cycle 4) 
Area % of treatments with  
first dose directly  
observed (DoT) 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 100.0% 
Labe, Lelouma 100.0% 
Siguiri, Mandiana 99.7% 




Table 21:Administration of the first daily dose of cycle 4 
Administration of the first dose of Cycle 4 % of children 
By the CHW 87.4% 
By caregiver, observed by CHW 12.2% 
By caregiver, unobserved 0.2% 







Reported adherence to the unsupervised doses of amodiaquine was very high. Of eligible children 
treated at cycle 4, caregivers reported that 96.8% received all three daily doses. Caregivers were 
asked if the child swallowed all the medicine, spat out some medicine, or vomitted all the 
medicine. Most responded the child swallowed the medicine without vomitting.  Of those who 
were treated, a total of 95.2% of children were reported to have received and swallowed the 3 
daily doses without vomitting. The most common reasons for not receiving SMC at cycle 4 were 
that the child or caregiver was away (Table 22, 23).  
Table 22: Reasons for missed treatments 
Reason % 
Child was away at the time 54.2% 
Child was living away from home 14.4% 
Caregiver not available 11.9% 
Other 6.0% 
Child was unwell 4.4% 
Family refused: state reason 3.9% 
Not eligible 1.7% 
The health worker did not visit the household 1.6% 
Too young 1.2% 
Child has history of allergies to drugs 0.4% 
Side effects 0.2% 
Child died 0.2% 
Number of responses: 536 
 




















Child was away at the time 55.6% 25.5% 82.7% 37.9% 31.0% 
Child was living away from home 4.9% 34.8% 2.1% 11.2% 30.3% 
Caregiver not available 8.9% 13.9% 0.3% 28.7% 19.9% 
Child was unwell 11.4% 17.6% 1.9% 4.7% 3.1% 
Other 10.0% 
 














The health worker did not visit the household 
   
5.5% 3.0% 






Child died 1.3% 









Total number of SMC treatments received by each child 
Children aged 3 to 59 months at the time of cycle 1 are eligible to receive SMC four times, and 
should receive all of these treatments to maximise their protection. The mean number of 
treatments per child was 3.1. Overall, 78.2% of children received SMC at cycle 1, 79.9% at cycle 2, 
77.4% at cycle 3 and 77.2% at cycle 4 (Table 24, 25), and 70.8% received four treatments (Table 
27).  Overall, 17.6% of children did not receive any SMC treatments. SMC was equitable in terms 
of wealth ranking and gender (Tables 29, 30). 
 
SMC coverage in each year since 2015 is compared in Table 26. 
 
Table 24: SMC coverage among children eligible for four treatments, by area (with 95%CI) 





Cycle 1 Cycle 2 Cycle 3 Cycle 4 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 3.3 81.9% 82.4% 83.0% 82.6% 79.8% 
Labe, Lelouma 3.6 89.0% 87.3% 90.4% 89.1% 89.3% 
Siguiri, Mandiana 2.2 54.8% 55.2% 55.6% 53.1% 55.5% 
Dabola, Kankan, Kouroussa 3.6 90.0% 88.4% 91.3% 89.3% 90.9% 
Pita,Mamou,Dalaba,Faranah 3.2 80.4% 81.7% 83.5% 79.3% 76.9% 
TOTAL 3.1 78.2% 78.2% 79.9% 77.4% 77.2% 
 




C1 C2 C3 C4 
Dinguiraye 181 71.9% 72.9% 72.4% 72.4% 
Gaoual 87 88.7% 87.1% 86.8% 86.8% 
Koubia 14 85.7% 92.9% 92.9% 50.0% 
Koundara 44 88.6% 88.6% 88.6% 88.6% 
Mali 81 93.7% 94.8% 94.8% 94.8% 
Tougue 43 86.0% 86.0% 83.8% 72.5% 
Labe 104 87.4% 90.5% 88.5% 88.9% 
Lelouma 30 87.0% 90.2% 90.2% 90.2% 
Siguiri 345 46.4% 46.4% 46.9% 46.9% 
Mandiana 199 79.6% 81.4% 70.4% 79.8% 
Dabola 88 81.2% 83.0% 80.1% 81.0% 
Kankan 426 96.3% 96.5% 95.9% 95.0% 
Kouroussa 272 73.9% 83.0% 78.4% 85.6% 
Mamou 93 83.6% 77.4% 66.7% 56.1% 
Pita 95 73.9% 77.9% 68.8% 66.9% 
Dalaba 46 98.2% 98.2% 98.2% 98.2% 





Table 26: Comparison of coverage 2015-2020: mean number of treatments per child in each 
year 
Prefecture 2015 2016 2017 2018 2019 2020 
Dinguiraye 3.25 3.65 3.99 3.82 3.29 2.90 
Gaoual 2.46 3.29 3.10 3.31 2.63 3.49 
Koubia 3.26 3.52 3.54 3.36 3.00 3.21 
Koundara 3.16 2.75 2.49 3.41 2.42 3.54 
Labé 
  
3.04 3.33 2.92 3.55 
Lelouma 
  
3.83 3.25 3.03 3.58 
Mali 3.20 3.40 2.97 3.80 2.92 3.78 
Mandiana 
 
3.46 3.49 3.85 3.37 3.11 
Siguiri 
 
3.48 2.12 1.43 1.78 1.87 
Tougé 3.50 3.89 3.79 3.58 3.02 3.28 
Dabola    3.30 3.85 3.25 
Kouroussa    3.67 3.49 3.21 
Kankan    3.29 3.20 3.84 
Pita      2.88 
Mamou      2.84 
Dalaba      3.93 
Faranah      3.25 
TOTAL 3.15 3.46 2.93 2.90 2.90 3.13 
 
 

















0 15.5% 9.4% 42.2% 5.1% 13.2% 17.6% 
1 0.7% 0.0% 0.4% 0.9% 2.7% 1.2% 
2 2.1% 0.9% 2.9% 3.4% 4.2% 3.1% 
3 4.0% 4.4% 4.9% 10.2% 9.5% 7.4% 
4 77.7% 85.3% 49.6% 80.4% 70.4% 70.8% 
At least 1 84.5% 90.6% 57.8% 94.9% 86.8% 82.4% 
 
SMC coverage in Siguiri: The prefecture with the lowest coverage is Siguiri. Out of 11 survey clusters in 
Siguiri, three were three where none of the children surveyed had received SMC: Balato, Fatoya, 
Franwalia Centre. In four villages, Kignekourou, Kouremale, Nanen Traore, and Talabe, less than 50% of 




Figure 7: SMC coverage in 2020, by zone. Coverage per cycle and the percentage of children 
who received four SMC treatments. 
 
Table 28: Probability tree for receiving SMC in each month.  
A total of 78.2% of eligible children received SMC in the first cycle, 77% received SMC at cycle 1 and cycle 
2, 73.4% received SMC at cycles 1,2 and 3, and 70.8 received all four cycles. At cycle 1, 21.8% did not 
receive SMC and most of these (17.6%) were also missed at cycle 2, 3 and 4. Few children who were 
missed at cycle 1 received SMC in later cycles. To improve coverage it is important to maximise the 
















No. C1 C2 C3 C4 
100 78.2 77.0 73.4 70.8 
       2.6 
    3.6 1.9 
      1.7 
  1.2 0.4 0.4 
      0.0 
    0.8 0.2 
      0.6 
 21.8 2.9 2.6 2.5 
      0.1 
    0.3 0.1 
      0.1 
  19.0 1.0 0.9 
     0.1 
   17.9 0.4 




Equitability of SMC coverage 
Table 29: SMC treatment by wealth ranking 
SES Mean number of  
SMC treatments  
(95%CI) 
% that received  
four SMC  
treatments 
% that received  
no SMC 
Lowest 3.28 73.8% 12.8% 
Low 3.15 68.3% 15.0% 
Middle 3.19 73.7% 17.4% 
High 3.19 72.7% 16.4%  
Highest 2.92 67.1% 23.3% 
Table 30: SMC treatment by gender 
Gender Mean number of  
SMC treatments 
% that received  
four SMC  
treatments 
% that received  
no SMC 
Boys 3.1 90.8% 18.0% 
Girls 3.1 70.8% 17.1%  
 
Figure 8: The % of eligible children that received 4 treatments, and that did not receive SMC, 














Lowest Low Middle High Highest
Wealth ranking
% of eligible children who received 4 SMC treatments, and % that did not receive 
SMC, by wealth group
% received 4 SMC
% Did not receive SMC
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Treatment of children above the age of 5 
Children who are 5 years of age and above at the time of the first SMC cycle, should not receive 
SMC. The dose has been calculated according to age and if children above the age of 5 are given 
the blister pack intended for the 12-59-month group, they may be under-dosed, this can select for 
resistance as parasites are exposed to sub-therapeutic doses of SMC drugs. Children aged above 
6 years at the time of the survey, should not have received SMC.  
 
465 children 6years and above were surveyed. 6.3% received an SMC card. 5.2% received SMC at 
each cycle (Table 31) 
 
Table 31: Treatment of children above the age limit for SMC (aged 6-7 years at the survey) 
 
 
Treated at cycle: 
   
 
Year Mean number  
of treatments 




2017 1.68 42.8% 43.9% 43.5% 38.2% 53.8% 189 
2018 0.63 16.3% 16.5% 15.3% 14.9% 17.5% 327 
2019 0.32 10.9% 9.6% 10.2% 1.8% 13.9% 244 






Bednet use by children and other household members 
 
A total of 7,028 household members who slept in the household the night before the survey, were 
surveyed in 1,374 households. (Note that the survey was limited to households that had at least 
one child under 7 years of age and aged at least 3 months and so is not fully representative of the 
total population).  
 
Bednet use in children under 5 yrs of age: 
In the survey after the 2017 SMC campaign, 43% of children in the survey (children eligible to 
receive SMC) were reported to have slept under a bednet the night before the survey.  In the 2018 
survey, 30.2% of children slept under a net the night before the survey. In the 2019 survey, 86% 
(95%CI 79%,90%) of children slept under an LLIN the night before the survey. In the 2020 survey, 
66% of children under 5 slept under an LLIN (Table 32). 
 
Table 32: Percentage of children 3-59months who slept under a LLIN the night before the 
survey, in 2019 and 2020 
Area % slept under a LLIN last night (95%CI) 
 2019 2020 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 87.1% (78.8%,92.4%) 76.6% (66.0%,84.7%) 
Labe, Lelouma  92.3% (88.4%,95.0%) 87.5% (72.3%,94.9%) 
Siguiri, Mandiana 75.9% (56.9%,88.3%) 38.7% (25.4%,54.0%) 
Dabola, Kankan, Kouroussa 90.7% (86.4%,93.8%) 73.1% (66.6%,78.8%) 
Pita,Mamou,Dalaba,Faranah (not surveyed) 67.7% (59.5%,74.9%) 
TOTAL 85.7% (79.2%,90.4%) 66.3% (60.1%,72.0%) 
 
 
Children above the age of 5 were less likely to use an LLIN than children under 5 (Figure 9, Table 
33). LLIN use is lowest at age 7yrs. This drop in LLIN use above the age of 5 was more marked in 
some areas than others (Figure 11). LLIN use was lower than in 2019, in all age groups and in all 
areas, the reduction was greatest in Siguiri and Mandiana (Figure 10). Most nets were less than 2 
yrs old (Figure 12). 
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Figure 11: Comparison of LLIN use by age group by zone: 
 
 


























Table 33: LLIN use (% slept under a LLIN the night before the survey) by age 
 
Age  LLIN use (95%CI) 
0-4yrs 66.2% (60.0%,71.8%) 
5yrs 59.6% (51.5%,67.3%) 
6yrs 55.8% (45.1%,65.9%) 
7yrs 45.1% (35.7%,54.9%) 
8yrs 50.6% (38.8%,62.3%) 
9yrs 62.8% (50.5%,73.7%) 
10-14yrs 55.2% (45.0%,64.9%) 
15-19yrs 55.8% (45.8%,65.4%) 
20-24yrs 71.4% (63.8%,77.9%) 
25-29yrs 66.3% (59.0%,72.9%) 
30-34yrs 62.2% (55.1%,68.8%) 
35-39yrs 65.0% (59.6%,70.1%) 
40-44yrs 51.3% (42.7%,59.8%) 





Of 1,377 households surveyed, 73.5% had at least one LLIN and 23.4% had one LLIN for every 2 
persons. This compares with 89.8% had at least one LLIN and 36.8% had one LLIN for every 2 
persons in the household, in 2019 (Table 34). 
 
Table 34: Access to a bednet: % of households with at least one net, and % of households with 
at least one net for every two people who slept in the household the night before the survey 
  % households (95% CI) 
At least one net per household 2020 73.5% (68.4%,78.6%) 
 2019 89.8% (84.7%,94.8%) 
 2018 39.7% (29.8%,49.5%) 
At least one net for every two persons 2020 23.4% (19.2%,27.5%) 
 2019 36.8% (30.6%,42.9%) 
 2018 13.1% (7.5%,18.7%) 
 
Access to a LLIN, the percentage of the population who could sleep under a LLIN if there were two people 
per net, was 25.4% in 2018. This increased to 68.2% in 2019, and decreased 52.3% to the current survey 
(Table 35). 
Table 35: Access to a LLIN. Percentage of the population who slept in the household the night 
before the survey, who could sleep under a net if two people slept under each net.  







No. of nets (LLIN) in the household  
  
 





in the  
household  
the night  
before  
the survey 











a net  
if 2/net 
1 66.9% 33.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3 33.1% 
2 6.1% 88.0% 2.5% 3.4% 0.0% 0.0% 0.0% 0.0% 0.0% 30 93.9% 
3 25.0% 59.5% 13.8% 1.3% 0.4% 0.0% 0.0% 0.0% 0.0% 210 55.2% 
4 30.1% 34.3% 30.8% 3.0% 1.5% 0.3% 0.0% 0.0% 0.0% 365 52.7% 
5 22.2% 22.9% 36.7% 16.3% 0.4% 0.0% 1.5% 0.0% 0.0% 320 56.7% 
6 30.3% 16.7% 29.6% 16.3% 3.7% 3.4% 0.0% 0.0% 0.0% 195 48.7% 
7 21.5% 12.5% 28.2% 27.6% 6.1% 3.3% 0.9% 0.0% 0.0% 119 53.6% 
8+ 31.4% 6.4% 15.0% 25.5% 9.2% 5.7% 4.6% 1.4% 0.9% 135 45.1% 




Caregivers were asked if they had experienced three or more of the following symptoms at the same time 
in the past 6 months: fever, cough, sore throat, shortness of breath, fatigue, aches and pains, headaches, 
runny nose, and if they had any of these symptoms now. A total of 0.3% said they had 3 or more of these 
symptoms now and 2.9% said they had 3 or more symptoms together at some time in the previous 6 
months (Table 36). 
A total of 7 people (0.6%, 95%CI 0.2%,1.6%) said they had been tested for COVID-19. A total of 4 people 
(0.2%, 95%CI 0.09%,0.6%) said they thought they had been in contact with someone who had tested 
positive. 
 
Table 36: Percentage of caregivers reporting symptoms associated with COVID-19:  
Current symptoms 
% (95%CI) 
Symptoms in the last 6 months 
% (95%CI) 
Fever 27.1% (5.5%,70.5%) 63.0% (49.4%,74.8%) 
Cough 84.9% (42.5%,97.7%) 32.8% (20.6%,47.7%) 
Sore throat 0% (0%,0.3%) 1.6% (0.4%,6.5%) 
Shortness of breath 15.9% (1.2%,74.1%) 2.8% (0.4%,16.3%) 
Fatigue 22.8% (3.0%,73.7%) 48.1% (34.3%,62.1%) 
Aches and pains 16.9% (1.5%,73.1%) 47.7% (34.9%,60.8%) 
Headache 38.8% (7.9%,82.5%) 65.7% (51.6%,77.6%) 
Runny nose 0% (0%,0.3%) 10.5% (5.2%,20.0%) 







Annex A: Sampling methods 
The primary outcomes to be assessed in the survey were the percentage of eligible children who received 
SMC in each cycle and the percentage of children who received SMC four times. Children aged 5-7 years 
were included in the survey to determine the extent of SMC treatment above the age limit. It was also 
planned to ask about adherence to SMC doses, and reasons for missed treatments, and (for all household 
members) the use of long-lasting insecticide-treated bednets (LLINs).   
The survey was designed to estimate SMC coverage with a precision of about +/-10% in each of four 
zones: 
Zone 1: Dinguiraye, Gaoual, Koubia, Koundara, Labe, Lelouma, Mali, Tougue 
Zone 2: Mandiana, Siguiri 
Zone 3: Dabola, Kankan, Kouroussa 
Zone 4: Pita, Mamou, Dalaba, Faranah  
and with a precision of about +/-5% for the overall estimates across the whole SMC area. 
Sample size calculation 
The margin of error on the survey estimates of SMC coverage, depends on the level of coverage, the 
number of children surveyed, the number of clusters, and the design effect. Children within the same 
cluster tend to be similar in terms of the number of SMC treatments they received, the design effect 
measures the effect of this on the precision of survey estimates of coverage. For a given total sample size, 
one obtains better precision by having more clusters and fewer children per cluster, but logistic 
constraints limit the number of clusters, due to travel time and cost, and also because to ensure sampling 
is not biased, care is needed in each cluster to map where the dwellings are, divide the map into 
segments, and then to ensure all dwellings in the selected segment are visited.  
 
If the coverage is 80%, the margin of error will be: +/- 1.96x√(Deff)x√[0.8x(1-0.8)/(bxC)] where C is the 
number of clusters, b the mean number of children surveyed in each cluster, and Deff is the design effect. 
The design effect is given by: Deff=1+(b-1)roh where roh is the rate of homogeneity. From last year's 
survey, the roh value for the percentage of children who received SMC per cycle was about 0.3. The 
average number of children per cluster was 28. The design effect 1+(28-1)x0.3=9.1. If we have 90 clusters, 
the margin of error on a coverage of 80% will be: 1.96x√[9.1x(0.8x(1-0.8)/(28x90)]=+/-4.7%. A smaller 
number of children per cluster, reduces the overall sample size but also reduces the design effect, so that 
a similar level of precision is possible using smaller segments. The average figure of 28 eligible children 
per cluster resulted from the segmentation which relies on using existing natural features (roads/paths 
and residential blocks) to demarcate segments. Smaller segments could be created but it is important to 
have clear segment boundaries to ensure objective selection of households. Within a zone with 24 
clusters, the margin of error would be: 1.96x√[9.1)x(0.8x(1-0.8)/(28x24)]=+/-9.1%. Segments should 
ideally be chosen to include about 10-15 eligible children and as before should also include children age 
5-7yrs to be able to determine the extent of treatment of older children. Clusters with 20 children aged 3 
months to 7 years would include about 15 children 3-59 months and 5 children 5-7yrs. Thus the total 




The survey was conducted in the prefectures of Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, Tougué, 
Dinguiraye, Siguiri and Mandiana, Dabola, Kouroussa, Kankan, Pita, Mamou, Dalaba and Faranah, which 
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implemented SMC in 2020.  A total of 90 settlements were surveyed in 2020, the same 66 settlements 
included in the 2019 survey plus an additional 24 settlements from Pita, Mamou, Dalaba and Faranah.  
The segmentation process is described in previous reports. Every dwelling within the chosen segment was 
visited and every child who was aged at least 3 months at the last cycle and was less than 7 years at the 
time of the survey, who had stayed in the house the night before the survey, was included in the survey. 
The GPS location of each dwelling visited was automatically recorded by the tablet PC used to collect 
interview data. The number surveyed in each settlement therefore could vary but the average was 
expected to be about 20 if the population data were accurate. There were 17 settlements that were 
selected which were too large for segmentation to be practical, and there was no information available 
about sub-divisions of these segments that could be used to select a smaller area. For these settlements, 
the total area was estimated by taking GPS locations around the perimeter of the inhabited area. A single 
location was then chosen, by randomly generating an x and y coordinate within the settlement (this was 
done independently of the survey team and the location sent to them by email). Interviewers surveyed 
houses around this point, recording the GPS location of each dwelling, and continuing outwards, without 
missing any dwellings, until the required number of children (20) had been reached. In the final dwelling, 





Table A1: List of clusters 







Dabola Banko Dalado - Daffela 1 0.900 374 
Dabola Dabola-centre Foundeng II - Foula 2 0.938 678 
Dabola Kindoye Kindoye II - Fissanya 3 0.913 484 
Dalaba Kankalabe Kankalabé Centre - Dinkoli Dow 4 0.500 1328 
Dalaba Mombeyah Gali - Lila 5 0.714 969 
Dinguiraye Banora Boubèrè - Boubèrè Centre 6 1.000 651 
Dinguiraye Diatifere Mamoudouya I - Bandianya 7 1.000 608 
Dinguiraye Dinguiraye-centre Tinkisso - Souloukoufalan 8 1.000 754 
Dinguiraye Selouma Selouma Centre - Sakabari 9 1.000 695 
Faranah Banian Banankoro - Banankoro Centre 10 1.000 2459 
Faranah Banian Kouratou - Kouratou Centre 11 1.000 940 
Faranah Beindou Niako - Niako Centre 12 0.846 1455 
Faranah Faranah-centre Aviation - Secteur SEG 13 0.917 197 
Faranah Faranah-centre Marché II - Gbeninkoro 14 1.000 2482 
Faranah Faranah-centre Sirikoloni II - Secteur III 15 0.800 211 
Faranah Faranah-centre Tonkolonko II - Secteur Quinsambou 16 1.000 815 
Faranah Heremakonon Dantilia - Kalia 17 0.941 368 
Faranah Maréla Boketo - Boketo Centre 18 0.929 96 
Faranah Maréla Misside Bolia - Dounketo 19 1.000 2528 
Faranah Passayah Soungbanya - Soungbanya Centre 20 0.917 618 
Faranah Tiro Almamya - Seceur Mosquée 21 1.000 173 
Faranah sandeniah Sandénia Mosquée - Secteur II 22 0.923 181 
Gaoual Foulamory Tabadian - Nyor Nyor 23 0.944 716 
Gaoual Koumbia Dara Bowé - Dara Bowé Centre 24 0.909 702 
Gaoual Malanta Kounsi - Peguéty 25 1.000 523 
Kankan Balandougou Koba - Koba Centre 26 1.000 632 
Kankan Bate-nafadji Djelibakoro - Total 27 1.000 1146 
Kankan Boula Kalafilila - Total 28 1.000 636 
Kankan Kankan-centre Aviation - Total 29 1.000 839 
Kankan Kankan-centre Briqueterie - Total 30 1.000 488 
Kankan Kankan-centre Farako I - Total 31 1.000 574 
Kankan Kankan-centre Hermakonon II - Total 32 1.000 435 
Kankan Kankan-centre Madina - Secteur II 33 1.000 511 
Kankan Kankan-centre Salamaninda - Secteur III 34 1.000 642 
Kankan Kankan-centre Timbo - Secteur II 35 1.000 610 
Kankan Koumban Koumban I - Koumban I Centre 36 1.000 621 
Kankan Missamana Djimbala - Secteur III 37 1.000 624 
Kankan Moribayah Moribaya Centre II - Moribaya II Centre 38 1.000 581 
Kankan Tinti-Oulen Gbanankoura - Total 39 1.000 636 
Kankan Tokounou Sansambaya - Sansambaya Centre 40 1.000 595 
Koubia Matakaou Matakaou Centre - Dougouwoulen 41 0.632 918 
Koundara Guingan Kifaya - Angona 42 0.929 799 
Koundara Sambailo Sambailo Centre - Thiuopoutel 43 0.792 820 
Kouroussa Balato Balato Centre - Fodedou 44 0.913 544 
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Kouroussa Banfele Nafadji - Total 45 0.947 201 
Kouroussa Cissela Fadoussaba - Total 46 0.933 108 
Kouroussa Cissela Sonokoro - Total 47 0.947 661 
Kouroussa Doura Farakoba - Farakoba Centre 48 1.000 635 
Kouroussa Kiniero Missamana - Total 49 1.000 615 
Kouroussa Kouroussa centre Doula - Kignedouba 50 0.941 635 
Kouroussa Kouroussa centre Wassabada - Secteur II (Raiko) 51 1.000 160 
Labe Garambe Garambé Centre -  Bassanya II 52 0.696 865 
Labe Labé centre Daka II -  Secteur II 53 0.731 234 
Labe Labé centre Madina -  Dianyabhè Mosquée 54 0.686 926 
Labe Noussy Kassangui -  Dow Kougue 55 0.750 5379 
Labe Tountouroun Tounny -  Gadha Thiolliwel 56 0.600 618 
Lelouma Lafou Bombi Bourou -  Yalaya 57 0.480 1306 
Lelouma Sagale Bamikountou -  Gnekori 58 0.524 1450 
Mali Donghol Sigon Dougaya - Dioma Roundé 59 1.000 625 
Mali Fougou Kansaghel - Laami 60 0.800 667 
Mali Madina Wora Pellissaré - Donghol Doubhi 61 0.727 678 
Mali Salambande Koya - Koya Centre 62 0.800 580 
Mali Yembereng Sinthiourou - Diaguitarè 63 0.900 635 
Mamou Gongoret Kourou - Hollandé Fougoun 64 1.000 681 
Mamou Mamou centre Loppé Ecole - Secteur III 65 1.000 717 
Mamou Oure Kaba Banikoto - Banirè Dionson 66 1.000 677 
Mamou Saramoussaya Nienouya - Diaberekouré 67 1.000 722 
Mandiana Balandougouba Sidikila II - Sidikila II Centre 68 0.913 704 
Mandiana Dialakoro Samory Touré - Samory TOURE 69 0.900 699 
Mandiana Kinieran Mbalia - Mbalia Centre 70 0.960 64 
Mandiana Koundian Koundian I - Namafouada 71 1.000 493 
Mandiana Morodou Samakofara - Samakofara Centre 72 1.000 592 
Pita Bantignel Bamtighel - Tokossèrè - Golea 73 0.733 963 
Pita Ley-Miro Fetowol - Loïgou Hakkoundè 74 0.692 710 
Pita Pita centre Guémé I - Ndantari I 75 1.000 748 
Pita Sintaly Lalya Mawndé - NDantary Toumanya 76 1.000 717 
Pita Timbi-Touny Péllel Bantan - Péllel Bantan Centre 77 0.917 799 
Siguiri Doko Kouremalé - Kouremalé Centre 78 1.000 1882 
Siguiri Franwalia Franwalia Centre - Franwalia Centre 79 1.000 1756 
Siguiri Kintinian Balato III - Balato Centre III 80 1.000 1566 
Siguiri Kintinian Fatoya - Fatoya Centre 81 1.000 1355 
Siguiri Malea Maléah Centre - Maléah Centre 82 1.000 633 
Siguiri Niagassola Kignekourou - Faraboloni 83 1.000 592 
Siguiri Norassoba NanenTraoré - Nanen Traoré Centre 84 1.000 674 
Siguiri Siguiri-centre Dankakoura - Dankakoura Centre 85 1.000 633 
Siguiri Siguiri-centre Saourou - Saourou Centre 86 1.000 746 
Siguiri Siguiri-centre Sougoula - Sougoula Centre 87 1.000 574 
Siguiri Siguirini Talabé - Talabé Centre 88 1.000 598 
Tougue Konah Bourouwal - Kounsen 89 0.938 589 




Annex B: Administrative data 
A total of 4.4 million treatments were administered in 2020 (4,355,326 treatments of which 626,433 
(14.4%) to infants and 3,728,893 (85.6%) to children), over four cycles. The number treated increased 
slightly in each successive cycle. The mean number treated per cycle was 1,088,832 (101% of target), 
and the number that received 4 cycles was 956,559 (89% of the target population). (These 
administrative estimates compare with survey estimates, detailed in the results section of this report, 
which are that a total of 82.4% of eligible children were reached (received SMC at least once), and 
70.8% of eligible children received 4 cycles.)   
Proportion of infants: The average percentage of infants treated over the 4 cycles, ranged from 10.4% 
(Dabola) to 19.5% (Mali). 
Referral: The proportion of infants and children seen during SMC visits who were unwell and were 
referred for treatment, differed significantly between cycles and between prefectures. In cycle 1, an 
average of 5.8 per 1000 infants were referred (ranging from 1.1/1000, in Gaoual, to 15.0/1000, in 
Mamou), and an average of 3.3 per 1000 children were referred (ranging from 0.7/1000, in Labe, to 
7.5/1000, in Mamou). In cycle 4, the average proportion referred was 1.3/1000 in infants and 0.5/1000 
in children. 
Exclusion for other reasons than illness: The proportion of infants excluded in the first cycle for 
reasons other than illness, was 24.6/1000, ranging from 0/1000 in Siguiri to 90/1000 in Labe, and the 
proportion of children excluded was 13.3/1000, ranging from 3.8/1000 (Tougue) to 31.7/1000 (Pita). 
Exclusions fell to 7.9/1000 in infants and 3.6/1000 in children in cycle 4. 
Refusals: In cycle 1, there were 3276 refusals, most of these (2499, 76%) were in Siguiri. The overall 
refusal rate in cycle 1 was 3 per 1000, but 15/1000 in Siguiri. The refusal rate was low in the subsequent 
cycles (overall, 3.1/1000 in cycle 1, 0.26/1000 in cycle 2, 0.17/1000 in cycle 3 and 0.11/1000 in cycle 
4). 
Vomitting: The proportion of infants and children who vomitted the first dose (and were given a 
replacement dose) in the first cycle, differed significantly by prefecture. Overall, 13/1000 infants were 
given a replacement dose in the first cycle, ranging from 3.8/1000 (Kankan) to 25.9/1000 (Mali), and 
4.7/1000 children (ranging from 1.7/1000 (Kankan) to 9.0/1000 (Faranah)). The proportion who 
vomitted decreased in successive cycles, in cycle 4 in total 6.9/1000 infants and 1.8/1000 children 




Table B1: Number of treatments administered in 2020* 
  Number of children treated Number treated as % of target population  
Prefecture Target C1 C2 C3 C4 C1 C2 C3 C4 % 
received 
4 cycles 
Dinguiraye 46996 44332 46633 48064 46620 94.3% 99.2% 102.3% 99.2% 92.7% 
Gaoual 46300 44667 45634 46174 46650 96.5% 98.6% 99.7% 100.8% 93.1% 
Koubia 23860 19751 22021 22865 23007 82.8% 92.3% 95.8% 96.4% 75.7% 
Koundara 31122 30178 31739 32101 31959 97.0% 102.0% 103.1% 102.7% 88.3% 
Mali 73099 71422 72315 72600 72678 97.7% 98.9% 99.3% 99.4% 88.8% 
Tougue 30708 30174 30409 30261 30363 98.3% 99.0% 98.5% 98.9% 91.8% 
Labe 75995 67906 74262 75031 75832 89.4% 97.7% 98.7% 99.8% 85.9% 
Lelouma 44907 43048 43819 44723 44510 95.9% 97.6% 99.6% 99.1% 92.1% 
Siguiri 162041 156520 165769 172682 173627 96.6% 102.3% 106.6% 107.2% 90.5% 
Mandiana 80344 85723 90324 93094 92081 106.7% 112.4% 115.9% 114.6% 101.5% 
Dabola 43319 41729 43186 44701 44888 96.3% 99.7% 103.2% 103.6% 90.1% 
Kankan 112777 109863 114554 115090 115489 97.4% 101.6% 102.1% 102.4% 92.2% 
Kouroussa 64191 58267 65781 65990 66078 90.8% 102.5% 102.8% 102.9% 81.0% 
Pita 66613 61816 67755 68150 68640 92.8% 101.7% 102.3% 103.0% 86.9% 
Dalaba 31951 29929 32894 33527 33035 93.7% 103.0% 104.9% 103.4% 89.9% 
Mamou 76244 65368 78722 81536 82421 85.7% 103.2% 106.9% 108.1% 80.9% 
Faranah 66998 57554 70762 73420 72613 85.9% 105.6% 109.6% 108.4% 79.4% 
Total 1077467 1018247 1096579 1120009 1120491 94.5% 101.8% 103.9% 104.0% 88.8% 
*includes a total of 18,091 treatments to non-residents 
 





Figure B2: Refusals, referrals and exclusions in cycle 1, by prefecture and age group 
 
 





Annex C: Seasonality of rainfall and malaria incidence 
 
Fig C1: Monthly rainfall patterns  
(data from https://en.climate-data.org/) 
 
Fig C2: Percentage of annual rainfall that fell in 3 months Jul-Sep in 2020  
 




















Table C1: The percentage of annual cases that occurred in 4 consecutive months, 5 months, 
and 6 months, in the age group of 5 years and above, 2015-2018.  
 
Age group 5+yrs 2015 2016 2017 2018 2015 2016 2017 2018 2015 2016 2017 2018
MALI 55 50 62 75 61 61 71 84 71 68 78 87
KOUNDARA 45 66 71 74 56 74 81 85 65 77 83 86
KOUBIA 66 59 70 74 78 69 78 83 83 77 85 86
LABE 53 60 70 72 69 74 80 84 83 82 88 88
LELOUMA 55 64 64 69 71 75 74 81 81 80 83 86
TOUGUE 58 61 68 68 67 71 79 83 75 81 86 88
GAOUAL 42 52 61 66 55 62 73 78 71 67 76 81
PITA 52 52 57 63 59 62 67 75 67 70 78 80
DALABA 48 56 53 56 61 65 64 67 65 74 75 75
MAMOU 41 57 53 56 45 68 64 66 57 77 73 73
DINGUIRAYE 53 51 52 55 62 63 63 66 69 70 72 74
BOKE 39 53 53 55 44 60 61 66 52 63 66 72
FRIA 50 52 50 54 57 59 59 64 67 67 68 70
DABOLA 53 56 59 53 62 67 71 64 70 77 80 73
KEROUANE 44 37 42 50 48 46 52 59 63 53 60 68
CONAKRY 59 51 49 50 66 58 59 59 74 64 65 65
KOUROUSSA 54 47 49 49 63 56 59 57 69 65 70 64
BOFFA 45 46 47 48 55 53 57 58 60 59 63 63
LOLA 60 41 40 48 65 50 50 54 67 59 59 63
KINDIA 58 45 43 46 67 54 52 55 73 61 60 63
DUBREKA 45 42 44 46 55 51 54 57 64 57 61 63
MACENTA 47 40 40 44 49 49 48 53 64 57 56 60
COYAH 53 43 43 44 59 52 53 55 65 59 60 60
FORECARIAH 52 47 45 43 60 57 56 55 71 64 64 61
TELIMELE 68 40 47 42 75 48 58 50 82 56 67 58
YOMOU 36 40 42 44 48 52 55 56 61
FARANAH 45 47 42 40 58 58 53 50 67 66 64 58
BEYLA 38 44 44 40 46 54 53 49 54 62 62 58
SIGUIRI 45 44 40 39 50 53 48 47 52 60 56 54
MANDIANA 46 39 55 48   63 56
NZEREKORE 53 45 40 38 64 55 49 47 71 63 58 56
GUECKEDOU 41 35 36 37 45 42 45 47 47 51 53 55
KISSIDOUGOU 49 39 42 36 58 48 53 45 64 57 63 54
KANKAN 40 42 46 36 48 52 56 44 54 60 64 53
CONAKRY/DIXINN 59 57 49 42 68 62 59 48 78 67 65 58
CONAKRY/KALOUM 70 51 42 52 76 59 51 63 84 64 57 70
CONAKRY/MATAM 65 56 54 55 70 62 63 64 77 67 68 69
CONAKRY/MATOTO 50 42 51 50 59 50 62 59 60 59 69 63
CONAKRY/RATOMA 53 48 47 49 57 57 58 59 68 64 65 64
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